Amphastar Pharmaceuticals (NASDAQ:AMPH) Sets New 1-Year Low - Should You Sell?

Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) reached a new 52-week low on Wednesday . The stock traded as low as $22.64 and last traded at $22.99, with a volume of 904517 shares. The stock had previously closed at $23.50.

Analyst Upgrades and Downgrades

Several research firms have commented on AMPH. Needham & Company LLC reaffirmed a "hold" rating on shares of Amphastar Pharmaceuticals in a report on Thursday, April 10th. Piper Sandler decreased their price target on Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a research report on Friday, March 21st.

Amphastar Pharmaceuticals Stock Down 2.2 %

The stock has a 50-day simple moving average of $28.33 and a two-hundred day simple moving average of $37.80. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. The firm has a market cap of $1.10 billion, a PE ratio of 7.66, a P/E/G ratio of 2.19 and a beta of 0.79.

Insiders Place Their Bets

In other news, CFO William J. Peters sold 4,231 shares of the company's stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total value of $116,521.74. Following the completion of the sale, the chief financial officer now owns 97,363 shares of the company's stock, valued at approximately $2,681,377.02. This represents a 4.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 27.10% of the stock is owned by insiders.

Institutional Trading of Amphastar Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in AMPH. Pacer Advisors Inc. grew its position in Amphastar Pharmaceuticals by 51,977.4% during the 4th quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company's stock worth $50,139,000 after acquiring an additional 1,347,775 shares during the last quarter. Wellington Management Group LLP bought a new stake in Amphastar Pharmaceuticals during the 3rd quarter valued at $957,000. Geode Capital Management LLC grew its holdings in Amphastar Pharmaceuticals by 1.5% in the 3rd quarter. Geode Capital Management LLC now owns 920,363 shares of the company's stock worth $44,674,000 after acquiring an additional 14,015 shares during the last quarter. D.A. Davidson & CO. purchased a new position in shares of Amphastar Pharmaceuticals in the fourth quarter valued at about $417,000. Finally, Barclays PLC raised its stake in shares of Amphastar Pharmaceuticals by 53.3% during the third quarter. Barclays PLC now owns 74,456 shares of the company's stock valued at $3,613,000 after acquiring an additional 25,878 shares during the last quarter. 65.09% of the stock is currently owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.